Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Durvalumab + domvanalimab versus durvalumab after concurrent chemoradiotherapy in unresectable stage III NSCLC
jRCT2061210088Phase 3Active, not recruiting
- Sponsor
- AstraZeneca
- Start
- Apr 2022
- Modality
- PD-1/PD-L1 Inhibitors → Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Phase 3, randomised, double-blind trial in non-small cell lung cancer (NSCLC) comparing Durvalumab + domvanalimab with Durvalumab + placebo (2 arms). Primary endpoint: Progression-free survival. Started Apr 2022; status: active, not recruiting.
02
Drugs
durvalumabdomvanalimab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on jRCT2061210088.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2061210088.